Ungefroren H, Gellersen B, Krull N B, Kalthoff H
Research Unit Molecular Oncology, Clinic for General Surgery and Thoracic Surgery, Christian-Albrechts University, 24105 Kiel, Germany.
J Biol Chem. 1998 Oct 30;273(44):29230-40. doi: 10.1074/jbc.273.44.29230.
In this study we demonstrate that the gene encoding the small leucine-rich proteoglycan biglycan is expressed in human myometrial tissue and in the human leiomyosarcoma cell line SK-UT-1. Treatment of SK-UT-1 cells with forskolin or 8-bromo-cAMP strongly increased biglycan mRNA and this effect was transcriptional as shown by transient transfection experiments with biglycan promoter-luciferase reporter fusion genes. The cAMP-mediated induction of the transfected biglycan promoter in SK-UT-1 cells was abolished by coexpression of a specific protein kinase A inhibitor, and was mimicked by overexpression of the catalytic subunit (Cbeta) of protein kinase A. By 5' deletion analysis, part of the cAMP response was localized to the segment from residues -78 to -46 of the biglycan promoter. This region conferred strong cAMP responsiveness to a heterologous promoter. Electrophoretic mobility shift and antibody supershift assays identified two specific complexes that contained nuclear proteins antigenically related to the ubiquitous transcription factors Sp1 and Sp3, respectively. The binding site of these proteins was mapped to a CT-rich sequence extending from -59 to -49 in the biglycan promoter. Mutating this sequence eliminated complex formation and markedly reduced basal and cAMP-dependent promoter activity of transfected reporter genes. In vitro binding studies using recombinant Sp1 revealed that the nuclear factor binding to the CT element was not Sp1 but a Sp1-like protein(s). Western blot analysis of SK-UT-1 nuclear proteins confirmed expression of Sp3, Sp1 and nuclear proteins that crossreacted with Sp1 antibody but according to their molecular weight were not Sp1. These results indicate that all cAMP-dependent as well as some basal biglycan transcription in SK-UT-1 cells is mediated through activated protein kinase A and that both functions are conferred at the promoter level through the interaction of Sp1-like/Sp3 factors with the CT element at -59 in the biglycan promoter.
在本研究中,我们证明编码富含亮氨酸小分子蛋白聚糖双糖链蛋白聚糖的基因在人子宫肌层组织和人平滑肌肉瘤细胞系SK-UT-1中表达。用福斯可林或8-溴-cAMP处理SK-UT-1细胞可强烈增加双糖链蛋白聚糖mRNA,如用双糖链蛋白聚糖启动子-荧光素酶报告基因融合基因进行的瞬时转染实验所示,这种效应是转录性的。在SK-UT-1细胞中,特异性蛋白激酶A抑制剂的共表达消除了cAMP介导的转染双糖链蛋白聚糖启动子的诱导作用,而蛋白激酶A催化亚基(Cβ)的过表达则模拟了这种作用。通过5'缺失分析,部分cAMP反应定位于双糖链蛋白聚糖启动子中从-78至-46位残基的片段。该区域赋予异源启动子强烈的cAMP反应性。电泳迁移率变动分析和抗体超迁移分析鉴定出两种特异性复合物,它们分别包含与普遍存在的转录因子Sp1和Sp3抗原相关的核蛋白。这些蛋白的结合位点定位于双糖链蛋白聚糖启动子中从-59至-49的富含CT的序列。突变该序列可消除复合物形成,并显著降低转染报告基因的基础和cAMP依赖性启动子活性。使用重组Sp1进行的体外结合研究表明,与CT元件结合的核因子不是Sp1,而是一种Sp1样蛋白。对SK-UT-1核蛋白的蛋白质印迹分析证实了Sp3、Sp1以及与Sp1抗体发生交叉反应但根据其分子量并非Sp1的核蛋白的表达。这些结果表明,SK-UT-1细胞中所有cAMP依赖性以及一些基础双糖链蛋白聚糖转录均通过活化的蛋白激酶A介导,并且这两种功能均在启动子水平通过Sp1样/Sp3因子与双糖链蛋白聚糖启动子中-59位的CT元件相互作用而赋予。